Institute of Clinical Medicine, Psychiatry, University of Eastern Finland, Finland; Institute of Clinical Medicine, Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Finland.
Institute of Clinical Medicine, Psychiatry, University of Eastern Finland, Finland; Institute of Clinical Medicine, Kuopio Musculoskeletal Research Unit (KMRU), University of Eastern Finland, Finland; Department of Psychiatry, Kuopio University Hospital, Finland; Departments of Psychiatry: South-Savonia Hospital District, Mikkeli, North Karelia Central Hospital, Joensuu, SOTE, Iisalmi, Finland.
Maturitas. 2022 Jan;155:63-69. doi: 10.1016/j.maturitas.2021.10.006. Epub 2021 Oct 21.
Mental disorders (MDs) and musculoskeletal disorders (MSDs) are the main causes of disability. Yet, their comorbidity has not received the deserved attention.
To investigate the extent of the comorbidity between MDs and MSDs in ageing women using national registries on prescription medications and work disability pensions (DPs).
The study included 7,809 Finnish women, born during 1932-41, from the population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE) cohort, established in 1989. Lifetime permanent DPs due to: 1) 'MDs only' (n = 359), 2) 'MSDs only' (n = 954), 3) 'MDs + MSDs' (n = 227), were recorded till 2003. The reference group was 'no DP' (n = 6,269). Data from the OSTPRE questionnaires was obtained in 1994. Use of medications was recorded in 1995 and 2003. The use of musculoskeletal or psychotropic medications by women having a DP or medication due to MD, or MSD diagnoses, respectively, was considered as an indicator of comorbidity.
In 1995, all DP groups had used psychotropic and musculoskeletal medications more often than the referents. Use of musculoskeletal medications was associated with a higher use of psychotropic medications, and vice versa (OR=2.45; 95% CI 2.17-2.77), compared with non-use. The 'MSDs only' group was more likely to use psychotropic (OR=1.79; 95% CI 1.50-2.12), and the 'MDs only' group musculoskeletal medications (OR=1.38; 95% CI 1.09-1.74), compared with those without DPs. The proportions of medication users were similar in 1995 and 2003; however, the amounts used increased.
There was strong evidence for comorbidity between MDs and MSDs in ageing women. Further research concerning their longitudinal relationships is warranted.
精神障碍（MDs）和肌肉骨骼疾病（MSDs）是导致残疾的主要原因。然而，它们的共病尚未得到应有的重视。
使用国家处方药物和工作残疾抚恤金（DPs）登记处，研究老年女性 MDs 和 MSDs 共病的程度。
本研究纳入了来自 1989 年成立的基于人群的库奥皮奥骨质疏松风险因素和预防研究（OSTPRE）队列的 7809 名芬兰女性，她们出生于 1932-41 年。因以下原因获得终身永久性 DPs：1）“仅 MDs”（n=359），2）“仅 MSDs”（n=954），3）“MDs+MSDs”（n=227），直至 2003 年记录。参考组为“无 DP”（n=6269）。1994 年从 OSTPRE 问卷调查中获取数据。1995 年和 2003 年记录药物使用情况。患有 DP 或 MD 或 MSD 诊断的女性使用肌肉骨骼或精神药物，被认为是共病的指标。
1995 年，所有 DP 组使用精神药物和肌肉骨骼药物的频率均高于参考组。与未使用相比，使用肌肉骨骼药物与更高频率的精神药物使用相关（OR=2.45；95%CI 2.17-2.77），反之亦然。与无 DPs 相比，“仅 MSDs”组更可能使用精神药物（OR=1.79；95%CI 1.50-2.12），“仅 MDs”组更可能使用肌肉骨骼药物（OR=1.38；95%CI 1.09-1.74）。1995 年和 2003 年药物使用者的比例相似，但使用量增加。
老年女性 MDs 和 MSDs 之间存在明显的共病证据。需要进一步研究它们的纵向关系。
